Nucleic acids encoding CRISPR-associated proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-11739335-B2
Application number	US-201816496518-A
Country	US
Kind code	B2
Filing date	Mar 23, 2018
Priority date	Mar 24, 2017
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.

First claim

The invention claimed is:

1. An artificial nucleic acid molecule comprising
a. at least one coding region encoding at least one CRISPR-associated protein comprising an amino acid sequence according SEQ ID NO: 428 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 428;
b. at least one 5′ untranslated region (5′ UTR) element; and
c. at least one 3′ untranslated region (3′ UTR) element,
wherein said artificial nucleic acid molecule is an RNA and wherein the at least one coding region comprises a nucleic acid sequence at least about 90% identical to one of the sequences of SEQ ID NOs: 2540-2553.

2. The artificial nucleic acid molecule of claim 1 , comprising
at least one 5′ UTR element derived from a 5′UTR of a HSD17B4 gene; or at least one 5′ UTR element derived from a 5′UTR of a NDUFA4 gene.

3. The artificial nucleic acid molecule of claim 1 , wherein said 3′UTR element is derived from a PSMB3 gene.

4. The artificial nucleic acid molecule of claim 1 , said artificial nucleic acid comprising a nucleic acid sequence encoding a CRISPR-associated protein comprising or consisting of an amino acid sequence according to SEQ ID NO: 428, or an amino acid sequence having at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 428.

5. The artificial nucleic acid molecule of claim 1 , wherein said CRISPR-associated protein comprises at least one further effector domain, selected from KRAB, CSD, WRPW, VP64, p65AD and Mxi.

6. The artificial nucleic acid molecule of claim 1 , wherein said artificial nucleic acid further comprises at least one nucleic acid sequence encoding a nuclear localization signal (NLS).

7. The artificial nucleic acid molecule of claim 4 , wherein the at least one coding region of said artificial nucleic acid molecule comprises a nucleic acid sequence according to any one of SEQ ID NOs: 2540-2553 or a nucleic acid sequence having at least 95% sequence identity to the any one of said nucleic acid sequences.

8. The artificial nucleic acid molecule of claim 1 , which comprises a 5′-CAP structure.

9. The artificial nucleic acid molecule of claim 1 , which comprises at least one histone stem-loop.

10. The artificial nucleic acid molecule of claim 8 , comprising a poly(A) sequence, comprising 10 to 200 adenosine nucleotides.

11. The artificial nucleic acid molecule of claim 4 , which comprises, in 5′ to 3′ direction, the following elements:
a) a 5′-CAP structure,
b) the 5′-UTR element,
c) the at least one coding sequence,
d) the 3′-UTR element,
e) a poly(A) tail,
f) optionally a poly(C) tail, and
g) optionally a histone stem-loop (HSL).

12. A composition comprising the artificial nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier and/or excipient.

13. The composition according to claim 12 , wherein the artificial nucleic acid molecule is complexed with one or more cationic or polycationic lipids.

14. A kit comprising the artificial nucleic acid molecule of claim 1 , and optionally a liquid vehicle and/or optionally technical instructions with information on the administration and dosage of the artificial nucleic acid molecule or the composition.

15. The artificial nucleic acid molecule of claim 1 , wherein the at least one 5′ UTR element is derived from a 5′ UTR of a gene selected from the group consisting of SLC7A3, ATP5A1, RPL32, HSD17B4, NOSIP, ASAH1, RPL31, TUBB4B, UBQLN2, MP68 and NDUFA4.

16. The artificial nucleic acid molecule of claim 1 , wherein the at least one 3′ UTR element is derived from a 3′ UTR of a gene selected from the group consisting of GNAS, CASP1, PSMB3, ALB, COX6B1, NDUFA1 and RPS9.

17. The artificial nucleic acid molecule of claim 11 , wherein the at least one coding region comprises a nucleic acid sequence at least about 90% identical to the sequence of SEQ ID NO: 2540.

18. The artificial nucleic acid molecule of claim 17 , wherein the at least one coding region comprises a nucleic acid sequence at least about 95% identical to the sequence of SEQ ID NO: 2540.

Assignees

• CureVac SE

Inventors

• Chevessier-Tünnesen Frédéric
• Poenisch Marion
• Schlake Thomas

Classifications

• C12N2310/531

  Stem-loop; Hairpin · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• A61K48/0066

  Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title